Interleukin-5 Antagonist [EPC]

50011 reported adverse events

Drugs of this class: MEPOLIZUMAB RESLIZUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-5 Antagonist [EPC] class:

# Side effect Count
0 ASTHMA 12822
1 DYSPNOEA 10661
2 WHEEZING 7159
3 PRODUCT DOSE OMISSION ISSUE 6648
4 COUGH 5136
5 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 5052
6 DRUG INEFFECTIVE 4684
7 PNEUMONIA 4668
8 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 4241
9 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 3118
See all common reactions for Interleukin-5 Antagonist [EPC]

Drugs of the Interleukin-5 Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PLETHYSMOGRAPHY 25 0.9615
1 TOTAL LUNG CAPACITY INCREASED 186 0.6889
2 SPUTUM CULTURE 25 0.6757
3 HEART SOUNDS 63 0.6562
4 AIRWAY REMODELLING 68 0.5528
5 HEPATIC ENZYME 73 0.5290
6 ASTHMA-CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME 255 0.4961
7 REVERSIBLE AIRWAYS OBSTRUCTION 226 0.4449
8 VITAL CAPACITY DECREASED 184 0.4135
9 TOTAL LUNG CAPACITY ABNORMAL 146 0.3883
See all enriched reactions for Interleukin-5 Antagonist [EPC]